clinical trial retatrutide A new from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Phase III retatrutide study demonstrates

Pilocarpine (Salagen) and cevimeline (Evoxac) are cholinergic agonists that directly stimulate salivary gland secretion

This unique mechanism has made Retatrutide one of the most discussed research peptides in recent years and a topic of growing interest among researchers studying body weight regulation, appetite control and metabolic health

These findings expand upon the growing body of literature raising concerns regarding the potential ocular safety of systemic GLP-1 RA use in patients with diabetes, investigators concluded

It is undergoing rigorous Phase 3 testing and has not yet received final approval from the FDA or MHRA for general prescription use

Psychiatrists (MD/DO) have full prescriptive authority to prescribe FDA-approved medications including GLP-1 agonists like semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) for weight loss, provided they follow standard of care and any state-specific rules

As GLP-1 medications become more widely used for metabolic health and weight management, interest in needle-free alternatives has surged